Leelyn Smith’s Inovio Pharmaceuticals INO Stock Holding History

Leelyn Smith’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	400
2021 Q3	$0	Hold	1	–	–	﹤0.01%	368
2021 Q2	$0	Hold	1	–	–	﹤0.01%	365
2021 Q1	$0	Hold	1	–	–	﹤0.01%	387
2020 Q4	$0	Hold	1	–	–	﹤0.01%	365
2020 Q3	$1K	Buy	+1	New	+$209	﹤0.01%	325
2020 Q1	–	Sell	-1	Closed	–	–	338
2019 Q4	$0	Buy	+1	New	+$30	﹤0.01%	318

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Leelyn Smith's INO Position: Q4 2021 in Review

Leelyn Smith sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 1 share.

Leelyn Smith first reported a position in INO in Q4 2019 and held it in 6 quarters. The position peaked at $1K in Q3 2020. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

Leelyn Smith reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Leelyn Smith sold 1 Inovio Pharmaceuticals share in Q4 2021.
Leelyn Smith first reported a position in Inovio Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Leelyn Smith's Inovio Pharmaceuticals position peaked at $1K in Q3 2020.
208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on Leelyn Smith's 13F filing for Q4 2021, filed 14 Feb 2022.